
Puma Biotechnology, Inc. (PBYI) Stock Ticker
PBYI right now
Market factors today
Unlock the full PBYI picture
About Puma Biotechnology, Inc.
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
PBYI stock facts
| Ticker symbol | PBYI |
| Exchange | NASDAQ Global Select |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $497.3M |
| CEO | Alan H. Auerbach |
| Employees | 179 |
| Headquarters | Los Angeles, CA, US |
| IPO date | 2012-04-24 |
| Website | www.pumabiotechnology.com |
What you can see for PBYI on Tickr
Live PBYI price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the PBYI report.
Rankings
FAQ
What is the ticker symbol for Puma Biotechnology, Inc.?
The ticker symbol for Puma Biotechnology, Inc. is PBYI, listed on the NASDAQ Global Select.
What is PBYI?
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic…